Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on March 27, 2025
ParaZero Signed Non-Binding Letter of Intent to Acquire a Company that Specializes in Counter-Drone Systems and Autonomous Drone Technologies
GlobeNewswire
·
March 27, 2025
Proposed acquisition would bring advanced space technologies and deep-space navigation expertise into ParaZero’s innovation portfolio TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero”), an aerospace …
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
GlobeNewswire
·
March 27, 2025
SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today provided shareholders with an update on its strategic and …
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
GlobeNewswire
·
March 27, 2025
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer …
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
GlobeNewswire
·
March 27, 2025
Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative …
Gauzy Ltd. to Attend Jefferies Virtual Cleantech and Utility Equipment Conference
GlobeNewswire
·
March 27, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ), a global leader of vision and light control technologies, today announced that its senior management will attend the Jefferies Virtual Cleantech and Utility Equipment …
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 27, 2025
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value- …
New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders
GlobeNewswire
·
March 27, 2025
Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson’s to be presented First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation Additional …
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 27, 2025
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven …
WALKER RIVER ANNOUNCES INTERCEPTS INCLUDING 2.62 G/T OVER 41.1 METERS AT THE LAPON GOLD PROJECT
GlobeNewswire
·
March 27, 2025
Vancouver, B.C., March 27, 2025 (GLOBE NEWSWIRE) -- Walker River Resources Corp. (“Walker” or the “Company”) (TSX-V: WRR) is pleased to announce additional assay results from the 2024 reverse circulation (“RC”) drill program at the Lapon Canyon portion of …
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well- …
Infinidat and Veeam Team Up on Next-Generation Data Protection for Kubernetes-based Workloads
GlobeNewswire
·
March 27, 2025
WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Infinidat, a leading provider of enterprise storage solutions, today announced that Veeam, a leader in Kubernetes data resilience, can now leverage Infinidat’s InfiniBox® high-performance, cyber resilient …
Nayax and N-and Group Forge Strategic Partnership to Offer Next-Generation Smart Screens with Embedded Payments
GlobeNewswire
·
March 27, 2025
HERZLIYA, Israel and BRISTOL, United Kingdom, March 27, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and …
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
GlobeNewswire
·
March 27, 2025
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( …
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
GlobeNewswire
·
March 27, 2025
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth …
Hudbay Consolidates 100% Ownership in its Copper Mountain Mine
GlobeNewswire
·
March 27, 2025
Increases Hudbay's exposure to a long-life, high-quality copper asset in Canada, a tier-1 mining jurisdiction Low upfront and deferred cash consideration in a transaction which is accretive to Hudbay’s net asset value per share Copper Mountain is expected …
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
GlobeNewswire
·
March 27, 2025
NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study …
Hudbay Provides Annual Reserve and Resource Update, Three-Year Production Outlook and Positive Snow Lake Exploration Results
GlobeNewswire
·
March 27, 2025
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “company”) (TSX, NYSE: HBM) today released its annual mineral reserve and resource update and issued new three-year production guidance. All amounts are in U.S. dollars, …
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
GlobeNewswire
·
March 27, 2025
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid …
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
GlobeNewswire
·
March 27, 2025
BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND …
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
GlobeNewswire
·
March 27, 2025
Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease Anticipate topline results in late 2026 Topline results from the Phase 1 study investigating a subcutaneous sabirnetug …